Laurent Pharmaceuticals
Private biopharmaceutical company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | CAD2.7m | Debt | |
| Total Funding | 000k | ||
Related Content
Laurent Pharmaceuticals is a biotechnology company dedicated to developing treatments for orphan diseases, with a particular focus on cystic fibrosis and COVID-19. The company operates in the pharmaceutical industry, targeting rare diseases that have limited treatment options. Laurent Pharmaceuticals serves patients suffering from these conditions, healthcare providers, and the broader medical community. The business model revolves around clinical development programs and securing financing through funds like the BioMed Propulsion Fund. Revenue is generated through the development and eventual commercialization of their proprietary treatments, as well as through partnerships and collaborations with other entities in the healthcare sector. The company has received health approvals to initiate clinical trials and is actively involved in research and development to bring innovative solutions to market.
Keywords: biotechnology, orphan diseases, cystic fibrosis, COVID-19, clinical trials, dual pro-resolving, antiviral, healthcare, pharmaceutical, innovation.